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My first quarterly meeting of the
Medical Staff is now under my belt. I
thank all of you who attended and made
contributions.
I was pleased to have Victor Greco,
MD, President of the Pennsylvania
Medical Society, provide his personal
insights into the battle being fought in
Harrisburg for TORT and CAT Fund
reform. To judge by the applause you
provided Dr. Greco, the members of our
staff appreciated his timely remarks. It
was obvious to me after Dr. Greco's
synopsis that much can be achieved
when physicians work together for a
common goal.
Here, at Lehigh Valley Hospital, we
have a tremendous amount of physician
talent and an almost equally ponderous
number of agendas. PennCARE,
LVPG, MATLV, IPA, physician loyalty
and citizenship are all hot topics that
sometimes incense and sometimes unify
elements of our staff. Simple minded
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and naive as I may be, I can't help but
think that there is much more strength
in us as a large, unified body than as a
herd of cats.
In fact, in this rapidly changing medical
environment, it can almost never be said
that an action taken by one group occurs
in a vacuum. More often it is the case
that decisions have a ripple effect
throughout the entire staff. As your
elected leadership, Troika wants to try
to attempt to represent individual
agendas with the understanding that it is
the entire body of physicians to whom
we are ultimately responsible.
To wit, the Medical Executive
Committee has reached closure on the
issue of an Infectious Disease (TB and
Hepatitis) Policy for the Medical Staff.
I must tell you that this was a hotly
debated issue which received
overwhelming, but not unanimous,
support. As a result, it will be proposed
that a set of guidelines relating to
communicable diseases be amended to
the requirement for a physical
examination prior to everyone's biennial
reappointment. This month, we discuss
the implications ofPennCARE partner
physicians potentially requesting
privileges at Lehigh Valley Hospital. It
has been suggested that upcoming
topics should include the status of
Patient Centered Care and the
expectations/rewards which are
associated with citizenship at Lehigh
Valley Hospital.
(Continued on Page 2)

(Continued from Page 1) .

On a much less philosophical and much
more practical note, the Board of
Trustees unveiled its plans for a
spectacular $35 million edifice which
will be known as the East Wing.
Hopefully, the vast majority of our staff
had the opportunity to familiarize
themselves with this plan when it was
available at both the Cedar Crest and
17th Street sites in March. This
building will enable the Board to fulfill
its longstanding pledge to unify all
inpatient acute care into one facility

while providing, in an effici'ent manner,
additional capacity for ambulatory
services as we enter the new
millennium.
I wish all my colleagues a Blessed
Easter and Happy Passover.

Robert X. Murphy, Jr., MD
President, Medical Staff

New Radiology Administrator Appointed
On March 10, Sheila M. Sferrella began
her new position as Administrator,
Radiology and Diagnostic Medical
Imaging.
Sheila comes to Lehigh Valley Hospital
from Pennsylvania Hospital where she
served as Administrative Director of
Radiology and Respiratory Care from
1993 to the present. Previously, she
served in management positions at
Germantown Hospital and Medical
Center, Philadelphia, Pa., and the
University of Maryland Medical
Systems, Baltimore, Md.

Sheila holds a Master's degree in
Administrative Sciences from The
Johns Hopkins University and a
Bachelor of Science degree in
Radiologic Technology from the
University ofMaryland.
Her office is located in Radiology
Administration on the first floor of
Cedar Crest & I-78. She may be
reached at 402-8086.

Aetna U.S. Healthcare Contractfor Outpatient Radiology Services
Effective March 1, 1997, Lehigh Valley
Hospital, 17th & Chew, and the
Allentown Breast Diagnostic Center
have been added to the Aetna U.S.
Healthcare contract for radiology
services.
Under the Aetna U.S. Healthcare
capitated contract, primary care
physicians now have the option of
selecting either Lehigh Valley
Diagnostic Imaging at 1230 S. Cedar

Crest Boulevard, or Lehigh Valley
Hospital, 17th & Chew, as their
designated site for outpatient radiology
services.
For more information or to inform
Aetna U.S. He.althcare of your
designated site for outpatient radiology ·
services, please contact your Aetna U.S.
Healthcare Provider Services
Coordinator at 1-800-624-0756.
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News from Medical·Records
)

Ambulatory Surgery History
and Physical
Histories and physicals are required on
all patients prior to having any type of
invasive procedures. A new "short
form" history and physical has been
developed and subsequently approved
by the Medical Record and Medical
Executive committees for use on
ambulatory surgery patients. The onepage history and physical (MRD-60)
may be ordered through the LVH
".
p1ck-and-pack" system.

Verbal Orders

)

The Medical Staff Bylaws state that
verbal orders must be signed by the
person giving the order within 24
hours following the time the order was
given. For your convenience in
promptly signing the entries, the
Nursing Staff is attaching a "sign
here" sticker to any verbal orders that
are taken from the medical staff. Any
order to which a "sign here" sticker
has been attached and has not been
signed by the time of patient discharge
will become a medical record
.
deficiency.

Authentication of Medical
Record Entries

1. Draw a single line through the
incorrect entry (without obliterating
the entry}, indicating "error,"
"incorrect entry," etc.
2. Date and initial the incorrect entry.
3. If an entry is accidentally omitted,
the entry should be made after the last
entry with an explanation of omission
and reason it is out of order.

Document Imaging Update
The document imaging project, which
will make medical records available
on line simultaneously to all users, is
progressing according to schedule. A
vendor (Imnet) has been selected,
functional specifications signed off
with the expectation of factory
acceptance of the equipment by midApril.
Tentative plans are underway to
implement Document Imaging at 17th
& Chew first sometime in June, 1997.
The Imaging Work Group is in the
process of scheduling meetings with
the departments involved at 17th &
Chew during the month of April to
assure a smooth implementation.

As a reminder, all entries in the
medical record must be signed and
dated by the person making the entry.

Corrections in the Medical
Record
)

Regulatory guidelines indicate that all
corrections in the medical record be
made in the following manner:
Page3

Cancer Staging Sheets
Effective May 1, 1997, cancer staging
sheets will be used to assign clinical
and/or pathologic stage to 46 organ
sites in compliance with American
Joint Committee on Cancer.
(American Joint Committee on
Cancer, Manual for Staging of
Cancer 1992, 4th edition, J.B.
Lippincott Co.) Documented
physician participation in the staging
process is a requirement for
accreditation by the Commission on
Cancer. Cancer staging sheets are
available for. these sites:
HEAD AND NECK

I

... Lip and oral cavity
... Pharynx (including base of tongue,
soft palate and uvula)
-+Larynx
... Maxillary sinus
... Salivary glands (parotid,
submandibular and sublingual)
... nyroid gland

I

DIGESTIVE

... Esophagus
... Stomach
... Small intestine
... Colon and rectum
-Anal canal
- Liver (including intrahepatic bile
ducts)
-Ampulla of Vater
- Exocrine pancreas
THORAX

MUSCULOSKELETAL

-Bone
-Soft tissues

-I
)

- Skin (excluding eyelid, vulva and
penis)
- Malignant melanoma

I

BREAST

-Breast

I

GYNECOLOGIC

... Uterus
... Cervix
-Ovary
-Vagina
-Vulva

I

I

GENITOURINARY

... Prostate
... Testis
... Penis
... Urinary Bladder
... Kidney
... Renal pelvis and ureter
... Urethra

I

OPHTHALMIC

)

I

· ... Eyelid
... Malignant melanoma, eyelid
- Conjunctiva
... Malignant melanoma, conjunctiva
- Malignant melanoma, uvea
- Retinoblastoma
... Sarcoma, orbit
- Lacrimal gland

I

CENTRAL NERVOUS

-Brain

-Lung
-Pleural mesothelioma

I

.SKIN

I

LYMPHOMAS

- Hodgkin's disease
- Non-Hodgkin's lymphoma

)

(Continued on Page 5)
Page4

Information Services Update
)

PHAMIS Fix for Screen Prints
Since the PHAMIS LastWord 3.11
upgrade in January, screen prints did not
display patient name and other
identifying information. PHAMIS has
now provided Lehigh Valley Hospital
was a "fix" for this situation and it is
currently in effect.
When you want to print the information
on the screen, press F2 or click on the
printer button in the-Toolbar. The screen
print will display the patient's medical
record number, last name, first name,
middle initial, birth date and age on the
top line of the printed page. If the patient
is an inpatient, you will also see the
facility, hospital service, unit, room and
bed, bedside phone extension, date of
admission, length of stay, and attending
physician on this top line. For
outpatients, you will see the facility, FD
(family doctor), and daytime phone
number.
The bottom line of the screen print
displays the advisory message (if any),
plus current date, current time, initials of
the current user, response time (in
seconds), screen ID, terminal name (Wnumber) and pathway.
·
Please remember that the printer button in
the Toolbar (or the F2 key on your
keyboard) is not designed to print entire
reports. It prints only what is seen on the
screen. If this is all you need, you will
now have the patient's medical record
number and name on the screen prints. If
you need the full transcription, ancillary
report, lab report, etc., please use the print
options within those specific modules.

PHAMIS LastWord Class
Schedule

physicians, residents, and allied health
personnel. All classes will be held in the
John and Dorothy Morgan Cancer Center
Training Room, Suite 401.
Wednesday, April2- 6:30 to 8 a.m.
Monday, April7- 6 to 7:30p.m.
Tuesday, April22 - 11:30 a.m. to 1 p.m:
Thursday, May 1- 11:30 a.m. to 1 p.m.
Tuesday, May 6- 6:30 to 8 a.m.
Tuesday, May 27 - 6 to 7:30p.m.
Thursday, June 12-6:30 to 8 a.m.
Wednesday, June 18- 11:30 a.m. to 1 p.m.
Thursday, June 26- 6 to 7:30p.m

Registration is required for all of these
sessions. Please contact Diann Brey at
402-1401 to register for a class.

liS Customer Service Changes
On Saturday, March 15, Information
Services reprogrammed the order of the
Customer Services HelpDesk selections
that you hear when you call402-8303.
This change was done to help simplify
the process and hopefully help the users
rol!te their calls to the correct and
responsible parties, resulting in better
turnaround time.

)

The new order of the HelpDesk selections
are as follows:

1.
2.
3.
4.
5.
6.

E-mail help
PHAMIS help
Security/Password help
Computer or Printer Hardware help
Office Automation Product help
None of the above

Therefore, if you need assistance from the
liS Customer Services HelpDesk, call
402-8303 and select the number from. the
above list which best matches your
problem.

Following is the schedule of classes for
PHAMIS LastWord training for

)
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Express CARE
)

On March 3, ExpressCARE was
instituted in the front of the
Emergency Department utilizing
rooms 2, 3, 4 and 5. This area has a
dedicated physician, nurse, and
support staff. From 11 a.m. until 7
p.m., Monday through Friday, use of
this area will be dedicated to the
ExpressCARE patient stream and will
be unavailable for other purposes.
This new process for delivering
emergency services has been designed

to enhance patient convenience and
satisfaction. The goal is to complete
the care cycle in 45 minutes. Within
the next few months, expanded hours,
including weekends, are being
planned.
If you have any questions, comments,
or concerns, please contact William
W. Frailey, Jr., MD, Vice President,
Care Management Systems, at
402-1770 or pager #5022.

Library News
The following books have recently
been purchased for the Health
Sciences Library at 17th & Chew:

)

Healthcare Standards 1997
Publisher: ECRI
Call No. W 22 AAl H422 1997
(Reference Book)

Multiple Pregnancy and Delivery
Author: Stanley Gall
Call No. WQ 235 M9606 1996
Chlld and Adolescent Psychiatry: A
Comprehensive Textbook, 2nd eel.
Editor: Melvin Lewis
Call No. WS 350 C53502 1996
These titles have been acquired for the
Library at Cedar Crest & 1-78:
Emergency Medicine Pearls: A
Practical Guide for the Efficient
Resident
Author: Adam Singer, et al.
Call No. WB 105 S617e 1996
The Biologic and Clinical Basis of
Infectious Diseases, 5th ed.
Editor: Stanford Shulman, et al.
Call No. WC 100 B616 1997

Current Library Hours
Cedar Crest & I·7.8
Monday through Friday
8:30 a.m. to 5 p.m.
17th &Chew
Monday through Friday
9 a.m. to 3:30 p.m.

OVID Training
If anyone is interested in scheduling a
brief, hands-on OVID training session,
please call Barbara Iobst at 402-8408. ·

)
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Congratulations!
David M. Caccese, MD, Chief,
Division of General Internal Medicine,
and Wayne E. Dubov, MD, Division
of Physical Medicine/Rehabilitation,
are the newly elected members of the
Board of the Greater Lehigh Valley
Independent Practice Association.
In addition, Dr. Caccese has also been
elected to the PHO Board as a
physician member.
Paul K. Gross, MD, Department of
Psychiatry, was recently informed by
the American Board of Psychiatry and
Neurology that he passed the
examination for certification of Added
Qualifications in Geriatric Psychiatry.

Jonathan Hertz MD, Division of
Pulmonary Medicine, has ·
satisfactorily completed training/
testing and has been designated a B
Reader in chest x-rays.
Jay H. Kaufman, MD, Division of
Pulmonary Medicine, was recently
informed by the American Board of
Internal Medicine that he passed the
November 1996 Recertification Fmal
Examination in Critical Care
Medicine.
Robert D. Riether, MD, Division of
Colon and Rectal Surgery, was
recently invited to join the Colorectal
Disease Committee of the National
Surgical Adjuvant Breast and Bowel
Project for a two-year period.

Papers, Publications. and Presentation
Mark A. Gittleman, MD, Division of
General Surgery, has been invited to
participate on the faculty of the postgraduate course, Image Guided Breast
Biopsy, of the spring meeting of the
American College of Surgeons to be
held in San Diego, Calif., April 5-9.
He will be teaching both breast
ultrasound and breast stereotactic
biopsy techniques.
Dr. Gittleman was also recently
invited, as a faculty member, for the
Southwestern Surgical Congress
meeting held in Keystone, Colo., at
the end of January, where he taught
both diagnostic and interventional
breast ultrasound techniques. Dr.
Gittleman is the program director for
the CME Category I approved course,
The Surgeon and Breast Ultrasound,
and has been invited to present this
course at numerous locations over the
past year.

)

Herbert "Chuck" Hoover, Jr., MD,
Chairperson, Department of Surgery,
recently participated as an
international faculty member in the
Gulf States Symposium for Cancer in
Riyadh, Saudi Arabia. He was a
course moderator and presented the
American College of Surgeons (ACS)
Cancer Management Course in his
role as co-chairman of the
International Cancer Management
Committee of the ACS 's Commission
on Cancer.
Peter A. Keblish, MD, Chief,
Division of Orthopedic Surgery, was a
co-author of a scientific paper titled
"In-Vivo Kinematic Analysis of
Mobile Bearing Total Knee
Prosthesis." The paper studied the
dynamic movement of patients' knees
(following total knee replacement)
(Continued on Page 9)
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(Continued from Page 8)

)

with squatting positions utilizing
fluoroscopy control. In order to analyze
knee movement under daily activities,
the studies were done at Lehigh Valley
Hospital in cooperation with the
Radiology Department.
The paper was also presented as a
scientific exhibit at the Orthopaedic
Research Society which preceded the
American Academy of Orthopaedic .
Surgery and the Knee Society meetings.
Lehigh Valley Hospital has been a
major institutional investigator for
mobile bearing total knees which are
becoming well accepted as the next
generation concept of knee replacement
arthroplasty.

)

As an invited guest of the Department
of Orthopedic Surgery, Dr. Keblish .
delivered the Grand Round lecture at
Yale-New Haven Hospital on March 7.
He presented a lecture on the Current
Status and Design Rationale of Mobile
Bearing Total Knee Arthroplasty and
also met with residents and staff for
case discussions and presentations.
Indru T. Khubchandani, MD, John J.
Stasik, Jr., MD, Lester Rosen, MD,
and Robert D. Riether, MD, Division
of Colon and Rectal Surgery, authored
the article, "Endorectal Repair of .
Rectocele Revisited," which was
published in the January 1997
periodical of the British Journal of
Surgery. The article was researched
and co-authored by James P. Clancy,
MD, Chief Surgical Resident at Lehigh
Valley Hospital.

)

/'

"Value of Carcinoembryonic Antigen
Monitoring and Curative Surgery for
Recurrent Colon and Rectal
Carcinoma," an article which was
published in the February, 1997 issue of
Diseases ofthe Colon and Rectum, was
authored by Paul Lucha, Jr., DO,

colon and rectal resident, Lester Rosen,
MD, Judy Olenwine, MS, Project
Coordinator, Department of Surgery,
James F. Reed III, PhD, Director of
Research, Robert D. Riether, MD,
John J. Stasik, Jr., MD, and lndru T.
Khubchandani, MD. The article
demonstrated the role of post-operative
CEA in curing selected patients with
recurrent colorectal carcinoma.
Edward M. Mullin, Jr., MD, Chief,
Division ofUrology, reviewed, edited,
and wrote an editorial comment for an
article which was published in a recent
issue of Urology. The article, "Effect of
Transurethral Indwelling Catheter on
Serum Prostate-Specific Antigen Level
in Benign Prostatic Hyperplasia," was
written by a group of Turkish
physicians.
Michael D. Pasquale, MD, Chief,
Division ofTrauma/Surgical Critical
Care, presented Practice Management
Guidelines for Trauma at the annual
meeting of the Eastern Association for
the Surgery of Trauma Plenary Session
which was held in Sanibel, Fla., in
January.
In addition, Dr. Pasquale recently
attended the annual meeting of the
· Society of Critical Care Medicine in
San Diego, Calif., where he presented
two posters, Cost Effectiveness of
Fever Evaluation Guidelines in the
JCU and Trends in Mortality and
Trauma Scoring in the Elderly
Trauma Patient. Also at the meeting,
Mark D. Cipolle, MD, Associate Chief,
Division of Trauma/Surgical Critical
Care, presented his poster,
·
Pentoxifylline and Ibuprofen Inhibit
Cytokine Release in Isolated Rat
Hindlimbs.
(Continued on Page 10)
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(Continued from Page 9)

Dr. Pasquale's article, "Acute
Appendicitis and the Use of
Intraperitoneal Cultures," was recently
chosen for inclusion in Selected
Readings in General Surgery, a reading
seminar in general surgery that is used
in teaching programs in the United
.States and Canada.

Robert D. Riether, MD, and John J.
Stasik, Jr., MD, recently attended a
Transanal Endoscopic Microsurgery ·
course for the removal of benign and
malignant tumors of the rectum which
was held recently for a week in
Tubingen, Germany.
Lester Rosen, MD, was part of a
Physician Advisory Panel to HCFA in
Baltimore, Md., on February 20. HCF A
has begun an "On Line" service in order
to promote relationships with hospitals,
providers, and beneficiaries. A

National Panel was assembled under a
contract awarded to the Barents Group,
in order to assess issues related to
Medicare.

)

The Department of Health Studies is
preparing the 1996 LVH Staff
Publications Yearbook. If you have
had any publications Oournal articles,
editorials, case studies, book
chapters, abstracts, letters, etc.) ·
throughout 1996, please make a
copy of the publication and mail it to
Bernadette Melon, Editor, Health
Studies, Moyer House, Lehigh Valley
Hospital, 17th &Chew, P.O. Box
7017, Allentown, PA 18105-7017.
Please make sure the name of the
journal and date of publication are
visible on the copy. If you have any
questions, please contact Bernadette
at 402-2529 or through e-mail.

)

Upcoming Seminars, Conferences and Meetings
Medical Grand Rounds

Department ofPediatrics

Medical Grand Rounds are held every
Tuesday from noon to 1 p.m., in the
hospital's Auditorium at Cedar Crest
& I-78.

A Pediatric symposium focusing on
Dermatology will be presented on
Thursday, April 17, from 1 to 5 p.m.,
in the Auditorium at Cedar Crest &
1::18. Paul Honig, 1\tiD, Chief.of
Dermatology at Children's Hospital of
Philadelphia, will be the main speaker.

Topics to be discussed in April
include:
April 1 - Infectious Disease
April 8 - Nephrology
April15- Hematology/Medical
Oncology
April 22 - Rheumatology
April29- Endocrinology

For more information, contact Kelli
Ripperger in the Department of
Pediatrics at 402-2540.

For more information, please contact
Becky Shennan in the Department of
Medicine at 402-8200.

)
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Who's New
)

The Who's New section of Medical Staff

Progress Notes contains an update of new

appointments, address changes, status
changes, etc. Please remember that each .
department or unit is responsible for updating
its directory and rolodexes with this
information.

Medical Staff

Appointments to Medical Staff
Leadership Positions
J. John Collins, MD
Co-Medical Director
Post Anesthesia Care Unit
(17th & Chew)
Bryan W. Kluck, DO
Medical Director
4A

)

Thomas M. McLoughlin, Jr., MD
Co-Medical Director
Operating Room
(Cedar Crest & I-78)
D. Lynn Morris, MD
Acting Director
Invasiv.e C~diology
Gary G. Nicholas, MD
Medical Director
4C
Walter J. Okunski, MD
Co-Medical Director
Operating Room
(Cedar Crest & I-78)
Orion A. Rust, MD
Medical Director
Mother/Baby Unit
and
Medical Director
Labor & Delivery Unit
Steven A. Scott, MD
Associate Medical Director
Lehigh Valley Transitional Skilled Unit

)

Change ofAddress and
Telephone_ Number
Lehigh Valley Nephrology Associates
Anthony Brown, DO
Robert S. Gayner, MD
Joseph M. Jacobs, MD
Robert N. Pursell, MD
30 Community Drive
Easton, PA 18045-2657
(610) 252-6950
FAX: (610) 252-8431
Michael L. Zager, MD
Lehigh Internal Medicine Associates
Atrium Building
2895 Hamilton Blvd
Allentown, PA 18104-6192
(610) 439-0303
FAX: (610) 439-1157

Resignations
Carol E. Anderson, MD
Department of Pediatrics
Division of General Pediatrics
Associate
Monica M. Dweck, MD
Department of Surgery
Division of Ophthalmology
Active
Raymond L. Weiand, DO
. Department of Surgery
Division of Orthopedic Surgery
Associate
Stacie Well, MD
Department of Obstetrics and Gynecology ·
Division of Gynecology
Section of Reproductive Endocrinology &
Infertility
Active

Allied Health Professionals

Resignation
Linda M. Woodin, MSN, CRNP
Physician Extender
Professional
RN
(Allentown Anesthesia Associates - Dr.
Maffeo)
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LIVER

(Including Intrahepatic Bile Ducts)
TNM CLASSIFICATION

RULES FOR CLASSIFICATION
Clln. Path.
T categories are based on the number of tumor nodules, the size r.N.;,X,:--~=.:.:;~~~=:;...===::....;:::==-+--=0:--~f---:0:---i
of the largest nodule (2 em is the discriminating limit), and the ...,.N=0'--;,=...:~=""""'""=-"==...;.==="'----+--:;§:=--1~§~
presence of vascular invasion. The staging system does not ._,N. :. .1:'---~=~=:..:....:...:;:====:....----.&.....::::......J~:-....~
consider etiologic mechanisms such as whether multiple nodules
represent multiple, independent primary tumors or intrahepatic
Distant Metastasis (M)
Clln. Path.
metastasis from a single primary hepatic carcinoma.
MX Presence of distant metastasis cannot be
0
0
assessed
Because of the tendency for vascular invasion, imaging of the
liver is important for staging primary hepatocellular carcinomas, MO No distant metastasis
0
0
unless distant metastasis is present at the time of diagnosis.
M1 Distant metastasis
0
0
Clinical Staging. Staging depends on some type of imaging
procedure to demonstrate the size of the primary tumor and
vascular invasion. Surgical exploration is usually not carried out,
because the possibility for complete resection is minimal,
especially for larger tumors.

Staae I
Staae II
Stage Ill

Pathologic Staging. If surgical exploration is carried out and
there is resection then Pathologic Staging can be recorded.

Note: For classification, the plane projecting between the bed of . Stage IVA
)e gallbladder and the inferior vena cava divides the liver into two Stag_e IVB
1obes.

TO
T1

T2

No evidence of orimarv tumor
Solitary tumor 2 em or less in greatest
dimension without vascular invasion
Solitary tumor 2 em or less in greatest
dimension with vascular invasion; or multiple
tumors limited to one lobe, none more than
2 em in greatest dimension without vascular
invasion; or a solitary tumor more than 2 em in
greatest dimension without vascular invasion

T3

Solitary tumor more than 2 em in greatest
dimension with vascular invasion; or multiple
tumors limited to one lobe, none more than
2 em in greatest dimension, with vascular
invasion; or multiple tumors limited to one
lobe, any more than 2 em in greatest
dimension with or without vascular invasion
T4 · ·Multiple tumors in more than one lobe, or
tumor(s) involving a major branch of the portal
or hepatic vein(s)

MO
MO
MO
MO
MO
MO
MO
M1

Clln. Path.
0
0
0
0
0
0

0

0

0

0

ESTABLISHED DIAGNOSIS (Readmission) NOT RESTAGED 0

DEFINITION OF TNM

Primary Tumor m
TX Prirnarv tumor cannot be assessed

STAGE GROUPING
T1
NO
T2
NO
T1
N1
T2
N1
T3
NO
T3
N1
T4
AnvN
AnyT
AnyN

Clln. Path.
0
0
0
0
0
0

0

0

Staged by: ----:-::=~=:--:::-:::=~-- M.D./D.O.
Attending Phyalclan Signature

Date: - - - - - -

0

0

0

0
Source: Manual for Staging, 4th Ed., American Joint Commission on Cancer

)
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Hospice Foundation of America
Fourth Annual Teleconference
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When Illness is Prolonged-,:.a,
Vloderator:
~anel:.

v-~.~~-;;..: ...l

Cokje Roberts, ABC and NPR Correspondent
Betty Davies. PhD, University of British Columbia
· Kenneth J Doka. PhD, College of New Rochelle
Dr. William Lamers. Jr., founding father of the American Hospice Movement
Therese A. Rando. PhD, Institute for the Study and Treatment of Loss

Local
sponsor:

contact Anne Huey
Lehigh Valley Hospice
at 402-7399.
April16, 1997
1:30pm EDT
Lehigh Valley Hospital, auditorium
Cedar Crest Blvd. & I -78

For more information,

Co-sponsored by:
Association of Death
Education and Counseling

In cooperation with:
American Medical Association

)

With supplemental funding from:
Project on Death in America

Join us for a local panel discussion
after the teleconference!

/

~- .

·.·.

' ..
......
-,. .\~ 2':\.:."'~ ·. ...
'

''··~,l:~.\:·~':

Moderator
Rev. Anne Huey, director of support services, Lehigh Valley Hospice
Panel
Bernadette Sychterz Cunningham. MTh, chaplain, Lehigh Valley Hospice
Kim Badillo. MA, RN, case manager, AIDS Activities Office
Lorraine Gyauch. MA. RN, director of the Family Caregiver Cancer Education Program, John and Dorothy Morgan Cancer Center
Jeanette Castellane. BA, gerontologist, Luther Crest
CEU's available upon request
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A supplement to medical records briefing

February 1997

Follow these guidelines to comply
with Medicare's new observation rules
by Kelly V. Butler, MD, CCS

I recently called a plumber for a problem with
my toilet. The plumber looked it over and said,
"You got plugged pipes." I said, "Fix it." And he
went to work. He took the toilet off and spent
the whole day there, and the problem was not
fixed by the time I came home. He came back
the next day to complete the job. The charges
were about $10 gazillion. So I paid and was very
happy until I found out that the insurance company would not cover the entire bill-because
the plumber had done much more than was necessary. The pliimber only needed to put a snake
through a pipe and my plumbing would have
)en unplugged in less than one hour.
Does this scenario sound familiar? Just like the
home insurance company that will not pay for
excess services, the days of the "blank check"
that allowed the attending physician to provide
any care, no matter the expense, are gone. A conscientious physician must provide his or her
patients with the least expensive care in a setting
that provides high quality. The physician should
always consider the basic question: What is the
lowest level of care that would be appropriate
for this patient's medical condition?
This question is especially important when placing patients under observation. If this service
isn't provided-and documented-exactly
according to the Medicare guidelines, reimbursement could be denied.
Who should be placed in observation?

A perfect candidate for observation is a patient
·yho is not sick enough to need inpatient serv,,tes but is too sick to send home. During the
observation period, the physician can safely

decide where he or she should place the patient
for care.
For example, if an asthmatic patient presents in
the emergency room with difficulty breathing,
the physician may believe the patient can be
cleared in a few hours. So the physician orders
an "outpatient observation admit," along with
aminophylline and respiratory treatments. If the
patient clears and is no longer wheezing in seven
hours, the physician can discharge the patient.
Rules to live by

When admitting patients for observation, however, physicians must follow the Health Care
Financing Administration's (HCFA's) strict rules,
which were released in Medicare Hospital Manual
transmittal numbers 689 and 699 and took effect
on October 1, 1996. The following are rules
physicians must follow to be reimbursed for
observation services:
1. The physician must write an order admitting

the patient to outpatient observation status. He
or she should be sure to write "admit to observation." This is very important. The physician·
cannot place the patient in observation when it
is medically appropriate to admit the patient
into an inpatient unit. And he or she cannot discharge a patient from the inpatient unit and
change the patient to observation status.
2. Similarly, if a patient is admitted to an inpatient unit with the reasonable expectation that he
or she will stay more than 24 hours, but the
patient is discharged and goes home before the
end of the first day, the physician cannot change
the patient's status to outpatient observation.

MRB, P.O. Box 1168, Marblehead, MA 01945. Telephone 617/639-1872. Fax 617/639-2982
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3. HCFA expects most observation patients to
be in the facility for less than one day. If a
patient is admitted during the first day of observation, this will count as the first inpatient day.
Some patients will require another day of observation. If a patient is admitted on the second
day of observation, the stay is billed as one day
of outpatient observation; the second day is the
first day of the inpatient stay.
4. If a patient is in observation for more than
two days, Medicare will reject the bill and deny
reimbursement for the services. The physician
can request an exception, but HCFA has said it
is "currently unable to envision any scenario"
that would result in a patient needing more
than 48 hours of observation. There is no preauthorization for these requests and the physician
must request the exception at the time of billing.
A copy of the medical record should be sent
with the bill.
Coverage exceptions

Outpatient observation services that Medicare
does not cover include:
1. Observation that exceeds 48 hours.
2. Services provided for the convenience of the
patient or doctor. For example, some patients
who have minor outpatient surgery may insist
on spending the night following the procedure.
However, if the physician adinits such a patient
for observation, Medicare will deny coverage.
The physician can bill the patient if the patient
is informed up front (in writing) that the
overnight stay is not medically necessary and
that the patient can be charged for that portion
of the bill. If the hospital does not do this in
writing and there is a denial by HCFA, that portion of the bill cannot be passed on to the patient.
3: Observation that should have been an inpatient admission.

4. Part B services that are an appropriate part of
other outpatient services. Patients require four
to six hours of care after an outpatient surgery
to recover from the anesthesia. These services
are included in the outpatient surgery charges
and should not be billed under observation status. However, if a patient has difficulty waking
up from the anesthesia after the usual time in
short stay surgery, the surgeon can write an
order for observation and have the patient monitored. When the patient recovers after five
hours in observation, he or she is discharged,
and the bill can include charges for the surgery
and the additional five hours of observation.

)

5. Standing orders for observation following
outpatient surgery.
6. Services ordered as inpatient by the admitting
physician but billed as outpatient by the billing
office.
7. Services that should have been provided as
inpatient care. A patient who has surgery and is
known to need at least an overnight stay should
be billed as an inpatient and not under the
observation billing.
Bill for the observation patient using the revenue code 762 and the HCPCS/CPT code 99902.
The number of hours that the patient was in
observation begins at the time he or she is
placed in the bed and is rounded up. The number of hours is used to specify the units of service provided.

Kelly V. Butler, MD, CCS, is a consultant with
Venture Healthcare, based in Chattanooga, TN. He
specializes in helping hospitals improve documentation and coding. If you-have questions or would like
A Minute for the Medical Staff to cover a particular topic, you may write to Butler, c/o Medical
Records Briefing, P.O. Box 1168, Marblehead,
MA, 01945.

A Minute for the Medical Staff is an exclusive seroice for subscribers to Medical Records Briefing.
Reproduction of A Minute for the Medical Staff is encouraged.
Reproduction in any form outside the subscriber's institution is forbidden without prior written permission.
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. As of April1 , 1997, Health Network Laboratories
will change its referred special endocrine testing
from Nichols to SmithKiine Beecham Clinical
Laboratory (SBCL). This was accomplished with
the full agreement of the Division of
Endocrinology/Metabolism. A majority of the
testing methodology will not change while
achieving reduced costs both to us and to the
patient. We will be forwarding to you a list of
tests that are affected with SBCL's specimen
requirements noted. Only three tests had
different specimen requirements: Renin,
C-Peptide, and APTH Related Protein. Any
additional changes will be handled by the
laboratory during specimen processing.
If you have specific test related interpretative
questions, our contact person at SBCL is Dr.
Steve Lobel at 1-800-523-0289, Ext. 5085. If
you are following a patient with a specific test
and have developed prior test history, please call
customer service at (610) 402-8170, so we can
arrange for between laboratory parallel studies to
establish a new baseline. New reference ranges
will be clearly noted on the patient report forms.
Two tests, Somatomedin-C and Urinary Cortisol
are remaining with Nichols Laboratory. For more
information or if you have any questions
regarding this issue, please contact Health
Network Laboratories Customer Service at
(610) 402-8170 ..

)

Lipid Evaluation Profiles: Do They
Require Revision?
The reorganization of routine chemistry profiles
was initiated last month and it is appropriate to
review other test panels. A lipid panel has its
CPT charge code (government acceptable) and
includes total cholesterol, direct measurement
HDL cholesterol, and triglycerides. In addition,
each test can be ordered separately with its own
CPT code. With the continuing emphasis on cost
. containment and an associated decrease in
·testing, Health Network Laboratories needs toreaccess its lipid profiles. These are:
Comprehensive Lipid Profile includes
measured Cholesterol, HDL-C, LDL-C,
Triglycerides, Apolipoprotein A, Apolipoprotein B,
and associated calculated ratios with
interpretations. This profile results in4-CPT
charge codes.
HDL·C, Cholesterol Panel includes measured .
cholesterol, HDL-C, LDL-C and triglycerides with
ratios and interpretations. This profile results in
2-CPT charge codes.
If ordered separately, both HDL-C and LDL-C will
involve a total cholesterol. Apoprotein A & B
cannot be ordered as separate tests but are only
available as part of the comprehensive lipid
panel. APO protein A is a direct measure of the
protein component of HDL fraction while
Apoprotein 8 is a direct measure of the LDL
protein fraction.
Page 17

In today's managed care environment with close
scrutiny of laboratory costs, should the
comprehensive lipid profile be discontinued?
Basically, this means that we retain the HDL-C
cholesterol panel and no longer offer the
lipoprotein measurements. With the increased
accuracy and precision of the HDL-C and LDL-C
tests, the apoprotein tests could be thought to be
. superfluous. Without the apoprotein
measurements, the CHD ApoA/ApoB risk ratio
calculation would not be available. The T-Chol/
HDL and LDL-C/HDL-C risk ratio would remain
with the current HDL-C cholesterol panel and
could be clinically adequate CAD risk ratio
predictors.
The three other suggested changes for lipid
panel orders are as follows. First, no lipid profile
be allowed on inpatients. Inpatients are in an
abnormal environment, often on heparin, and
either factor results in questionable lipid values.

Heparin absolutely causes an uninterpretable
lipid profile. Secondly, no fipid profiles be ·
completed on patients with triglycerides greater
than 1000 mg/dl. The turbidity and fat content of
the serum solution with the associated increase
in VLDL influence the accuracy of the laboratory
methods. Third, do not complete lipid profiles on
patients with total cholesterol less than 100
mg/dl. (This cut off could be raised slightly and is
open for comment.)

)

The laboratory is encouraging comments/
concerns/questions. Please contact either John
J. Shane, MD, Chairperson, Department of
Pathology; David G. Beckwith, PhD, Vice
President, Network Laboratory Services and
Clinical Director, Health Network Laboratories; or
Gerald E. Clement, PhD, Technical Director, at
402-8150.

)
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P & T HIGHLIGHTS
The following actions were taken at the December-1996, January, February-1997 Pharmacy and Therapeutics Committee
Meeting Maria Barr, Pharm.D., BCPS, Barbara Leri, Pharm.D., Howard Cook, R.Ph, BCNSP, FASHP

BRAND NECESSARY

)

. Some confusio.n. has arisen regarding
"Brand Only" dispensed medications. A
statement appears at the bottom of the
physicians order sheet which states
"authorization is hereby given to dispense
the generic or chemical equivalent unless
specifically underlined by the physician. "
Many physicians may underline the names
of the medications through habit, leading
to confusion when dispensing medications
which the institution may only carry
generically. To eliminate the confusion,
the Pharmacy and Therapeutics Committee
noted. to amend the statement to read
"authorization is hereby given to dispense
the generic or. chemical equivalent unless
specified as Brand Medically Necessary by
the physician," in keeping with other
prescription blanks widely used. The
statement must be written with the order
for the medication, if deemed, the brand
name of the product is necessary.

OLANZAPINE, A
PROMISING NEW
ANTIPSYCHOTIC

In the field of psychiatry, new agents are
not frequently released by the FDA due to
difficulties in testing and numerous side
effects these agents possess. Olanzapine
(ZyprexaR, Lilly) is a new antipsychotic
·presented to the Committee for approval to
· the LVH formulary. It is indicated for the

}

treatment of schizophrenic and other
psychotic disorders. Other agents
presently .carried on the LVH formulary
include clozapine, haloperidol, risperidone
and phenothiazines. Some of the potential
adverse effects include postural
hypotension, somnolence, constipation,
weight gain, dizziness and akathisia.
Advantages of olanzapine over the other
agents include equal efficacy with
haloperidol for short term control of
chronic schizophrenia. It is touted to have
a low propensity for inducing
extrapyramidal reactions compared to other
agents. Most importantly, there have been
no reports of agranulocytosis or seizUres
which are the serious concerns with
clozapine. It is recommended to initiate
therapy with low doses of 2.5-5mg daily
initially and increase to lOmg/day over
several days. One flaw in the medication
profue is the lack of comparative efficacy
to clozapine, its nearest structured relative,
in humans. Hopefully, studies will
become available in the future.
· Olanzapine will cost $4.30 for the 5 and
7mg strengths and $6.45 for lOmg dosage.
Though this seems relatively high, there is
no mandatory weekly CBC draws
necessary for olanzapine patients which are
required for clozapine patients. LVH will
maintain clozapine on the formulary
temporarily for continuation of therapy of
patients admitted to the hospital with plans
to remove it in 1-2 years based on
suspected low usage.
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SEVERE, SERIOUS
ALBUMINS%
SHORTAGE! THINK

HETASTARCH!

Mid-February, LVH was informed of a
nationwide shortage of Albumin 5% with
an INDEFINITE release date. Four
manufacturers of Albumin are responsible
for the U.S. supply. Two of the four
manufacturers have had recalls on their
5% stock due to bacterial contamination
and the presence of particulate matter. As
a result, the demand on the remaining. two
manufacturers is very high. Please note
presently we are still able to obtain 25%
Albumin, but potentially a shortage of this
concentration may ensue shortly.
An e-mail has been distributed to division
chiefs discussing the issue and outlining
alternative therapy options for Albumin
5 %. Highlights of the information
·
distributed is a follows:
The most common reason for 5% Albumin
to be used, is to increase BP or urine
output postoperatively once the patient has
been given an adequate fluid challenge
with a crystalloid such as NSS or Lactated
Ringers. After the patient has received
usually a maximum of 2L of crystalloid,
the physician may tum to a colloid for
effect, since colloids will remain in the
intravascular space and decrease the risk
of fluid overload leading to peripheral and
pulmonary edema.
Other reasons for albumin include: to
maintain or increase oncotic pressure when
a patient has severely low serum albumin
(i.e. < 2gm/dl), large weepy wounds or
to maintain cerebral perfusion pressure in
patients with subarachnoid hemorrhage,
and pancreatitis. These patients usually

use 25% Albumin with round the clock
administration and need t~ pull
extravascular fluid intravascularly.
Hetastarch 6% 500ml should be
recommended as the alternative for 5 %
Albumin 500ml or 250ml in the following
situations:
·
1.
Platelet count is > SOk, since there
2.
3.
4.

is a caution with the use of Hetastarch with
thrombocytopenia.
Normal renal failure. If patient still has
any renal function, hetastarch can be used.
No severe bleeding disorders, such as
ITP, etc.
Not a CNS (head injured patient).
Hetastarch can cause an increase in ICP's.

Usual Adult dose of Hetastarch (500ml
Hetastarch = 500ml 5% Albumin): 3060gm (500-lOOOml) Hetastarch over 1-2
hours. Usual daily dose = 20ml/kg/day to
a maximum of 1500ml/day. Slight lab
abnormalities have been seen with platelet
function, PT and PTT, not associated with
an increase in clinical bleeding, with
volumes of > 1500ml/day.

)

In severe renal impairment (est. CrCl
< lOml/min), use the same initial dose but
subsequent doses should be reduced by 2550%.
Hetastarch Precautions and Contraindications include:
1.

2.

3.

4.

Caution in patients with
thrombocytopenia.
Caution with patients with a history
of liver disease with underlying elevated
bilirubin.
Contraindication for the management of
cerebral vasospasm associated with
subarachnoid hemorrhage.
Contraindication in patients with severe
bleeding disorders, renal failure with
oliguria or anuria.

)
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Hetastarch Adverse Effects include:

.
)

1.
2.

3.
4.

Increased SED rate.
May interfere with platelet function
and cause transient prolongation of PT,
PTT and clotting times.
May slightly decrease platelet/hemoglobin
concentrations due to dilutions.
May increase serum amylase but is not
associated with pancreatitis.

The CDC lists the following situations in
which the use of vancomycin is
appropriate or acceptable: ·
1.

2.

For your information, the hospital costs
for colloids are as follows:
Albumin 5% 500ml
Albumin 5% 250m!
Albumin .25% 1OOml
Albumin 25% SOml
Hetastarch 6% 500ml

)

$90.00
$45.00
$90.00
$45.00
$31.00

Please limit your prescribing of Albumin
5 % whenever possible. If patients truly
necessitate Albumin 5% administration,
please indicate the reason for use on the
order to avoid having the pharmacist
calling the prescriber. If possible, attempt
to use lower volumes, such as 250ml vs
500ml Albumin for first line and monitor
effects. The patient may only require
250ml to achieve the desired outcome and
this would help preserve our presently low
stock.
A concerted effort by all staff will assist
the hospital in reserving our present supply
for our critically ill patients who truly
need Albumin therapy.

HELP CONTROL
RESISTANT
ENTEROCOCCUS

Vancomycin use has been reported as a
risk factor for infection and colonization
with VRE and may increase the possibility
of emergence of vancomycin - resistant
S. aureus and/or S .epidermidis. MMWR
Sept. 22, 1995.

3.

4.

5.

Treatment of documented or suspected**
serious infections with a resistant gram
positive organism (i.e. methicillin resistant
Staph aureus-MRSA, or methicillin
resistant Staph epidermidis-MRSE).
Treatment of a staphlstrep or other gram
positive infection in patients with serious
allergy to penicillin .Q! cephalosporin
(described as hives and/or respiratory
distress and/or collapse within minutes of a
dosage of a penicillin .Q! cephalosporin):
OR, if history of the reaction is
unobtainable.
PO vancomycin for antibiotic-associated
enterocolitis (due to c.difficile colitis)
which has failed to respond to
metronidazole OR is severe and potentially
life threatening.
Use as surgical prophylaxis iil patients
with a serious allergy to penicillin or
cephalosporin (described as hives and/or
respiratory distress and/or collapse within
minutes of a dosage of a penicillin .Q!
cephalosporin): OR, if history of the
reaction is unobtainable.
Endocarditis prophylaxis as outlined by the
American Heart Association for penicillin
.Q! cephalosporin allergic patients.

L VH was recently evaluated for
vancomycin use in accordance to the CDC
guidelines. Results of our review showed
a 33.7% use of vancomycin in surgical
prophylaxis, poor documentation ·of allergy
reactions in the medical record and lack of
documentation of reason for vancomycin

use.

Prescribers are urged to consider the
guidelines with all use of vancomycin and
document reason for use in patient's
medical record.
** Empiric therapy with vancomycin for a
suspected resistant gram-positive organism should
not exceed 3 days if cultures are negative and
infection ruled out.

)
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SHORT COURSES OF

BACTROBAN IS BEST

Mupirocin (Bactroban) is a widely used
topical antimicrobial ointment. Literature
over the past several years has shown an
increase in resistant gram-positive
organisms (i.e. Staph. aureus) with
prolonged usage > 5 days. In an effort to
curb resistance at LVH, the Pharmacy and
Therapeutics Committee has instituted a 5
day automatic stop for mupirocin orders.
· A reorder notice will appear on charts of
patients receiving mupirocin to notify the
prescriber to reevaluate the topical
therapy.

ZAFIRLUKAST
(ACCOLATER) LEUKOTRIENE
RECEPTOR ANTAGONIST
FOR ASTHMA
Zafrrlukast (AccolateR, Zeneca) has been
approved for use at LVH for the
prophylaxis and chronic treatment of
asthma in adults and children 12 years of
age and older. It is the frrst of a new
class of agents-selective leukotriene
receptor antagonists.

The leukotrienes (LTs), a family of
inflammatory mediators arising from the
metabolism of arachidonic acid via the
· 5-lipoxygenase pathway, produce effects
that mimic many aspects of asthmatic
symptomatology. Increased urinary levels
of LT's have been measured following
inhaled antigen challenge in susceptable
volunteers. Both eosinophils and mast
cells, prominent players in the
pathophysiology of asthma, have the
ability to produce leukotrienes.

Zafirlukast blocks early and late asthmatic
response, decreases exercise-induced
asthma (EID), and produces improvement
in daytime ashtma symptoms, night time
awakenings, rescue beta-agonist use, FEV,
and morning peak-expiratory flow rate. It
is not indicated for the reversal of
bronchospasm in acute asthma and should
not be used to treat acute episodes of
asthma; however, it may be continued
during acute exacerbations of asthma.

)

Adverse effects of Zafirlukast include
headache, respiratory infections, nausea,
diarrhea and generalized pain. It 1s an
inhibitor of cytochrome 2C9 and 3A4.
Coadministration with agents metabolized
by CYP2C9 (warfarin, tolbutamide,
phenytoin and carbamazepine) or CYP3A4
(cyclosporine, cisapride, astemizole,
dihydropyridine calcium-channel blockers)
should be closely monitored until
pharmacokinetic studies are available.
Coadministration with theophylline results
in reduced Zafrrlukast plasma levels, but
no changes in theophylline
pharmacokinetics.

)

The recommended dose is 20mg twice
daily' administered 1 hour before or 2
hours after meals. Dosage adjustments
are not necessary in elderly patients or
patients with renal dysfunction. The need
for dosage adjustments in hepatic
dysfunction has not been assessed. It is
available as 20mg tablets.
Zileuton (ZyfloR, Abbott) a 5-lipogenase
inhibitor, has recently been released for
the same indications. Its QID dosing
schedule, need for regular liver function
studies, and significant interactions with
theophylline and other agents make it an
unattractive agent for formulary
consideration.

)
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INJECTABLE
MULTIVITAMIN
SHORTAGE

There is currently a national shortage of
adult parenteral multivitamin formulations,
created by the discontinuation of on~
manufacturer's product and the exhaustion
of the current equivalent product, Astra's
MVI-12. Currently, LVH has adopted the
following guidelines, based on suggested
treatment options provided by the
· American Society of Paren~eral and
Enteral Nutrition:
1.

2.

)

3.

Use oral multivitamin supplementation
whenever possible. Oral liquid
formulations are available for those
patients with feeding tubes.
Preferential use of parenteral multivitamins
for all parenteral nutrition patients. This
group will receive multivitamin infusion on
Tuesday, Thursday, Saturday and Sunday
while supply lasts, or until the shortage
subsides.
For all other parenteral multivitamin
requests (and when current parenteral
nutrition multivitamin stores are
exhausted), the pharmacy has been
approved by the Pharmacy and
Therapeutics Committee to automatically
substitute the following:'
- Folic Acid lmg injection
- Cyanocobalamin 1OOmcg injection
-Thiamine lOOmg injection

TREAT HYPERTENSION
SAFELY- A VOID
SUBLINGUAL
NIFEDIPINE

The immediate release formulation of ·
nifedipine given by the sublingual or "bite
and chew" route has become a popular
treatment choice for acute hypertension.
All calcium-channel blockers cause
vasodilation, which decreases peripheral
resistance; short-acting nifedipine causes
the onset abrupt vasodilation, which can
result in myocardial ischemia. The risks
associated with it's use was recently
published in JAMA. Based on the recent
literature, a subcommittee of the Pharmacy
and Therapeutics Committee developed the
algorithm. (See Attachment A)
The algorithm should serve as a tool to
assist the health care provider with the
decision to treat and available agents and
alternatives to sublingual nifedipine.

This policy will continue until the current

shortage has ended. It should be noted
that injectable ascorbic acid is also
available for use, as indicated.

pt\297.hi
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ADULT HYPERTENSION ALGORITHM

Definitions:
Hypertensive Emergency: Situation that requires immediate BP reduction to prevent or limit target-organ damage.
Hypertensive Urgency - Situation in which it is desirable to reduce BP within 24 hours

BP ~ 180/100 mm Hg on
2 consecutive readings
yes I
Physical Exam (PE)
fundascopic
UA, PMH
I

I

Na Nitroprusside, Hydralazine,
Enalaprilat, labatolol, Methyldopa,
Nlcardipine, Diazoxide,
Trimethaphan

-----

"9

CD
CD
N
Ul

I

Monitor

I

-

Treat::
Determine if
IV or PO agent
to be used

Consider stress/anxiety/pain
as cause and treat accordingly
ie. benzodiazepine,
narcotics

I

no
Effective

JJ.JU

Clonidine, Labetolol,
Hydralazine, Captopril,
Nifedlpine PO?

I
j

yes

.J

PARENTERAL AGENTS DOSING TABLE
DRUG

DOSE

ONSET

CAUTIONS

Na Nitroprusside (NiprideR)

0.25-10mcg!K.g/min
IV infusion

instantaneous

Renal irrq:iaired patient
and/or· with prolonged
use may cause
thiocyanate intoxication

hydralazine (ApresolineR)

10-20mg IV bolus
10-40mg IM

10 minutes
20-30 minutes

Tachycardia, angina

enalaprilat (VasotecR)

0.625mg - 1.25mg IV
Q6brs

15-60 minutes

Bilat. renal artery
stenosis.
Contraindicated in
pregnancy.

labetolol (Trand;ateR)

5-10 minutes
20-80mg IV bolus
Q10 minutes, 2mglmin IV
infusion

methyldopa (Aldomeft)

250-SOOmg IV infusion
Q6brs

nicardipine (CardeneR)

5mglhr IV infusion
(0.1/ml cone) inc~ase by
2.5mglhr QS minutes to
max 15mgfhr then titrate
down to 3mglhr

diazoxide (HyperstatR)

50-150mg IV bolus,
repeat, or 15-30mg/min
IV infusion

1-2 minutes

Tachycardia, angina,
hyperglycemia with
repeated dosing

trimethapban camsylate

1-4mg/min IV infusion

1-:5 minutes

Paresis of bowel and
bladder orthostasis

:l

Bronchoconstriction
CHF
heart blOck

30-60 minutes
Large fluid volume
required

)

ORAL AGENTS :posiNG TABLE
DRUG

DOSE

ONSET

clonidine (Catapresll)

0.1-0.2mg PO, repeat
Qlhr to total dose of
0.6mg

30-60 minutes

labetolol (TrandateR)

200-400mg PO,· repeat

30-120 minutes

hydralazine (Apreso!ineR)

25-50mg PO, repeat
Q3-8 hrs

1/2-1 hour

Tachycardia

captopril (CapotenR)

25mg PO, repeat as
required

15-30 minutes

Renal artery stenosis.
Contraindicated in
pregnancy

nifedipine (Procardialt)

10-20mg fQ

15-30 minutes

Do not administer SL
QR bite and chew and
swallow. Rapid,
uncontrolled reduction in
blood pressure may
precipitate circulatory
collapse, ischemia, etc.

Q2-3 hrs

CAuriONS

Bronchoconsbiction

heart block
CHF

Angina

Page 26

LOOKING FOR: ALL MEDICAL STAFF WHO DID

·

RESIDENCIES AT LEHIGH VALLEY HOSPITAL

)

No matter if it was five, ten, twenty or over thirty years ago, if you did your residency here at
LVH, keep reading! Do you ever think back about the endless work, those long nights, and of
course the fun times and the friendships you made? Have you ever wondered where your
former colleagues are today? You'll soon be able to answer this question and more!
To "get the ball rolling", we're pleased to announce the formation of the LVII Resident Alumni Association.
After joint meetings with physicians, the Center of Educational Development and Support, and Developmentthe Association's Advisory Board met for the first time recently. LVH Co-Chairs and Alumni Thomas Meade,
MD '84, Patrice Weiss, MD '96, and Headley White, MD '61 are leading a fourteen member Board in ·
spearheading this effort.
Did you know there are over eighty former Lehigh Valley Hospital residents right here in the greater Lehigh
Valley! It may surprise you to learn how many of your colleagues are alumni! This effort, endorsed by Dr.
Sussman as well as by the hospital's Board ofTrustees, re-connecting with hundreds ofLVH alumni across the
country will soon become a reality.·
All alumni are invited to attend a LYH Resident Alumni Breakfast Open House. scheduled for the morning
of the upcoming Third Annual Managed Care Symposium, Saturday May 17, at 7:30am in Classroom 1.
(Forum begins at Sam in CC Auditorium). Stop by for breakfast, and learn more about your Resident Alumni
Association!
Questions! Please contact Jody Millard, Director ofAnnual Giving and Alumni Affairs, Development
Department, ext. 3036.

)

-------~-----------------~--------------~------------~-----------~-------------~-------------~-----------

Resident Alumni Association Data Form:

Name

-----------------------------------

Yes, I did my residency at LVH from _____ {year) to _ _ _ (year) in --....----=---..,.----(Clinical specialty)
Other LVH education? (ie: residencies, fellowships, etc.)_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Address preferred for "Al\Ull11i" correspondence: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
- - - - - - - - - - - - - - - - - - - - - - - - - - - - P h o n e : _ _ _ _ _ _ _ _ ____

CJ

Yes, I will be attending the Alumni Open House Breakfast on Saturday May 17 ·
in CC Classroom One at 7:30am

CJ

No, I cannot attend the breakfast, but please keep me informed.

)
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Elizabeth A. Khan MD
Tilghman Urgent Care
4825 Tilghman Street
Allentown, PA 18104-9374
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